Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Biota Pharmaceuticals Inc    NABI

SummaryNewsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Operates as an anti-infective drug development company

Aviragen Therapeutics, Inc. is a biopharmaceutical company focused on the discovery and development of products to prevent and treat serious and potentially life-threatening infectious diseases.

The Company currently has two Phase 2 clinical-stage product candidates in development: laninamivir octanoate, a long-acting neuraminidase inhibitor that the Company is developing for the treatment of influenza A and B infections under an investigational new drug application (IND) in the United States through a contract with the U.S. Office of Biomedical Advanced Research and Development Authority (BARDA) that is designed to provide up to $231 million in financial support to complete its clinical development; and vapendavir, a potent, oral broad spectrum capsid inhibitor of enteroviruses, including human rhinovirus (HRV).

In addition to these clinical-stage programs, the Company has a preclinical program focused on developing treatments for respiratory syncytial virus (RSV).

Aviragen Therapeutics was founded on November 8, 2012 and is headquartered in Alpharetta, GA.
Managers
NameAgeSinceTitle
Joseph M. Patti, PhD522012President, Chief Executive Officer & Director
Russell H. Plumb MBA, CPA572012Executive Chairman
Mark P. Colonnese MBA, CPA602015Chief Financial Officer & Executive Vice President
Anna Novotney-Barry-2013Vice President-Clinical Development
John H. Vernachio, PhD-2014Vice President-Preclinical Development
Geoffrey F. Cox, PhD722012Independent Non-Executive Director
Anne M. VanLent682013Lead Director
Michael R. Dougherty582013Independent Non-Executive Director
John P. Richard, MBA592013Independent Non-Executive Director
Armando Anido, MBA582015Director
Equities
Vote QuantityFloatCompany-owned sharesTotal Float
Share A 1 38,636,946 34,779,401 90.0% 0 0.0% 90.0%
Shareholders
NameEquities%
Broadfin Capital LLC 3,486,711 9.02%
East Hill Management Co. LLC 3,456,520 8.95%
Krensavage Asset Management LLC 2,625,239 6.79%
Senzar Asset Management LLC 2,025,976 5.24%
Fidelity Management & Research Co. 963,882 2.49%
BlackRock Fund Advisors 570,262 1.48%
Renaissance Technologies LLC 526,905 1.36%
BVF Partners LP 350,776 0.91%
Landon Thomas Clay 327,672 0.85%
The Vanguard Group, Inc. 287,119 0.74%
Sector
Healthcare
Pharmaceuticals & Medical Research
 Biotechnology & Medical Research
  Biotechnology & Medical Research
   Bio Therapeutic Drugs
Advertisement
Sector Biotechnology & Medical Research
Growth (Revenue) Profitability
GILEAD SCIENCES, ..
AMGEN, INC.
CELGENE CORPORATI..
REGENERON PHARMAC..
VERTEX PHARMACEUT..
ACTELION LTD
MEDIVATION INC
GENMAB A/S
JUNO THERAPEUTICS..
TONGHUA DONGBAO P..
HUALAN BIOLOGICAL..
NEUROCRINE BIOSCI..
INTERCEPT PHARMAC..
PEPTIDREAM INC
CHINA BIOLOGIC PR..
BEIJING SL PHARMA..
ULTRAGENYX PHARMA..
KITE PHARMA INC
ZHONGYUAN UNION C..
ANHUI ANKE BIOTEC..
Sector Biotechnology & Medical Research
Biota Pharmaceuticals Inc : Connections
Zygogen LLC
AMV Advisors
Beacon Street Advisors LLC
Lakewood-Amedex, Inc.
International AIDS Vaccine Initiative, Inc.
QUE Oncology, Inc.
Axotect, Inc.
Georgia Venture Partners LLC
Phase4 Partners Ltd.
Massachusetts Biotechnology Council
Altiris Therapeutics, Inc.
Altherx, Inc.
Mereo Biopharma Group Ltd.
Shire ViroPharma, Inc.
SciStem Therapeutics, Inc.
Cempra Pharmaceuticals, Inc.
Company contact information
Aviragen Therapeutics, Inc.
2500 Northwinds Parkway
Suite 100
Alpharetta, GA 30009

Phone : +1.678.221.3343
Web : www.aviragen.com
© 2016 People , Fundamentals and Ownership